Syros Pharmaceuticals Inc (NASDAQ:SYRS) – Research analysts at Oppenheimer increased their Q1 2018 earnings per share (EPS) estimates for shares of Syros Pharmaceuticals in a research note issued to investors on Monday. Oppenheimer analyst L. Cann now expects that the company will post earnings per share of ($0.59) for the quarter, up from their prior forecast of ($0.88). Oppenheimer has a “Buy” rating and a $28.00 price target on the stock. Oppenheimer also issued estimates for Syros Pharmaceuticals’ Q2 2018 earnings at ($0.72) EPS, Q3 2018 earnings at ($0.74) EPS, Q4 2018 earnings at ($0.77) EPS, FY2018 earnings at ($2.83) EPS, FY2019 earnings at ($2.12) EPS, FY2020 earnings at ($0.19) EPS and FY2021 earnings at $1.70 EPS.

Other equities analysts have also issued reports about the company. Zacks Investment Research raised Syros Pharmaceuticals from a “hold” rating to a “buy” rating and set a $11.00 price objective on the stock in a research note on Friday, January 5th. HC Wainwright reaffirmed a “hold” rating and issued a $10.00 price objective on shares of Syros Pharmaceuticals in a research note on Thursday, December 21st. Cowen reaffirmed a “buy” rating on shares of Syros Pharmaceuticals in a research note on Monday, December 11th. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $30.00 price objective on shares of Syros Pharmaceuticals in a research note on Tuesday, October 31st. Finally, Roth Capital started coverage on Syros Pharmaceuticals in a research note on Monday, October 23rd. They issued a “neutral” rating and a $15.00 price objective on the stock. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $22.23.

Shares of Syros Pharmaceuticals (NASDAQ SYRS) opened at $10.73 on Thursday. The company has a market capitalization of $280.06 and a PE ratio of -6.17. Syros Pharmaceuticals has a fifty-two week low of $6.30 and a fifty-two week high of $24.38.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings results on Wednesday, November 8th. The company reported ($0.53) EPS for the quarter, meeting the consensus estimate of ($0.53).

A number of institutional investors and hedge funds have recently modified their holdings of SYRS. Schwab Charles Investment Management Inc. bought a new position in Syros Pharmaceuticals during the 2nd quarter worth $343,000. Rhumbline Advisers bought a new position in Syros Pharmaceuticals during the 2nd quarter worth $198,000. Bank of New York Mellon Corp grew its stake in Syros Pharmaceuticals by 157.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 30,024 shares of the company’s stock worth $483,000 after buying an additional 18,382 shares during the last quarter. Teachers Advisors LLC grew its stake in Syros Pharmaceuticals by 360.5% during the 2nd quarter. Teachers Advisors LLC now owns 22,718 shares of the company’s stock worth $366,000 after buying an additional 17,785 shares during the last quarter. Finally, TIAA CREF Investment Management LLC grew its stake in Syros Pharmaceuticals by 646.3% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 34,390 shares of the company’s stock worth $553,000 after buying an additional 29,782 shares during the last quarter. Hedge funds and other institutional investors own 57.96% of the company’s stock.

In other news, Director Srinivas Akkaraju purchased 109,774 shares of the stock in a transaction dated Thursday, December 14th. The stock was acquired at an average cost of $9.03 per share, for a total transaction of $991,259.22. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Jeremy P. Springhorn purchased 15,000 shares of the stock in a transaction dated Friday, December 15th. The stock was purchased at an average price of $9.08 per share, with a total value of $136,200.00. The disclosure for this purchase can be found here. Corporate insiders own 33.60% of the company’s stock.

WARNING: This piece was first published by Daily Political and is the property of of Daily Political. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this piece can be accessed at https://www.dailypolitical.com/2018/01/11/q1-2018-eps-estimates-for-syros-pharmaceuticals-inc-syrs-lifted-by-oppenheimer.html.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.

Earnings History and Estimates for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.